CRISPR IND Updates: E. coli, Beta Thalassemia, and...
Jan. 12, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Poseida Therapeutics
Main focus: CAR-T cell therapies and liver-directed gene-editing therapies
Company stage: Clinical
Diseases: B-cell, multiple myeloma and solid cancers
Genome editing technology: Cas-CLOVER
Funding stage: Public (NASDAQ:PSTX)
Location: San Diego, CA, USA
Website: https://poseida.com/
Pipeline: https://poseida.com/science/pipeline/
Partnerships: Takeda Pharmaceuticals
Poseida Therapeutics is a clinical-stage CAR-T and gene editing company. The company is focused on treating various cancer types such as multiple myeloma, prostate cancer and B-cell malignancies. Poseida uses a proprietary gene-editing technology known as Cas-CLOVER in order to induce multiple edits in the genomes of its CAR-T cell products.
